Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in TAP Blocks
Launched by TATA MAIN HOSPITAL · Jun 15, 2015
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. Routine NPO protocols will be followed. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique in Triangle of Petit with 2 inches 24 G needle.
Patients would receive 75 mg of intramuscular diclofenac sodium immediately on shifting to the postoperative care unit (PACU) and a second dose 12 hours later. The time after the TAP block when rescue analgesia was first sought, total dose of required morphine in 24 hou...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • ASA 1 or 2
- • Age above 18 years
- • Patients for Lower Section Cesarean Section surgery
- Exclusion Criteria:
- • Patient refusal
- • Allergy to study medications
- • Localized infection over injection point
- • Patients with significant coagulopathies and with contraindications to regional anesthesia
- • Patients with a history of cardiac, respiratory, renal or hepatic failure
- • Psychological disorders
- • Chronic use of pain medications or adrenoreceptors agonists or antagonists.
- • BMI \>35 or weight \< 50 kilograms
About Tata Main Hospital
Tata Main Hospital (TMH) is a leading healthcare institution in India, renowned for its commitment to excellence in patient care, research, and education. As a prominent sponsor of clinical trials, TMH fosters innovative medical research aimed at advancing treatment options and improving health outcomes. With a multidisciplinary team of experienced healthcare professionals and state-of-the-art facilities, TMH is dedicated to conducting rigorous clinical studies that adhere to the highest ethical standards and regulatory requirements. The hospital's collaborative approach and focus on patient-centric research contribute to the development of safe and effective therapies, enhancing the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jamshedpur, Jharkhand, India
Patients applied
Trial Officials
Priti Gehlot, DA
Principal Investigator
Tata Main Hospital, Jamshedpur, India
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials